Grant GrossMendelsohn LLC Sells 200 Shares of Edwards Lifesciences Co. (NYSE:EW)

Grant GrossMendelsohn LLC lessened its position in Edwards Lifesciences Co. (NYSE:EW) by 2.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,658 shares of the medical research company’s stock after selling 200 shares during the quarter. Grant GrossMendelsohn LLC’s holdings in Edwards Lifesciences were worth $567,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of EW. Dimensional Fund Advisors LP increased its position in shares of Edwards Lifesciences by 18.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock valued at $129,271,000 after acquiring an additional 219,486 shares during the last quarter. Edgestream Partners L.P. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $438,000. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after buying an additional 184 shares during the last quarter. Inspire Investing LLC bought a new position in shares of Edwards Lifesciences in the second quarter valued at $1,015,000. Finally, Brighton Jones LLC increased its holdings in Edwards Lifesciences by 10.0% during the second quarter. Brighton Jones LLC now owns 3,742 shares of the medical research company’s stock worth $346,000 after buying an additional 339 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $69.77 on Friday. The company’s 50 day moving average price is $71.99 and its two-hundred day moving average price is $71.60. The firm has a market capitalization of $41.15 billion, a P/E ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.59 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a report on Thursday. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.48.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,000 shares of company stock worth $2,195,180. Company insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.